Aevi Genomic Medicine, Inc. (GNMX)

[420man]

An RS here would only be useful for the Company to further dilute retail in order to continue to fund their tests that just failed the endpoint standards. Thus the reason for the huge sell off.

It's oversold in relation to the chart, but IF they can't accomplish positive testing, they will have to submit to dilutive financing or sell off whatever they have that's of value. Read the filings! Sad actually, when considering their efforts and intent appear to be to help those suffering from ADHD and Chrons disease.